SCHEMBL3217423

SCHEMBL3217423

CC1=C(C)C(=O)C(CC[C@@H](C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)C)=C(C)C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.68
PTPN2 P17706 2/20 0.68
CDC25B P30305 2/20 0.68
IDO1 P14902 1/20 0.49
LMNA P02545 1/20 0.45
PTGS1 P23219 1/20 0.43
PDE4A P27815 1/20 0.43
SNCA P37840 1/20 0.43
PDE3A Q14432 1/20 0.43
BLM P54132 1/20 0.39
ALOX15 P16050 3/20 0.36
FNTA P49354 1/20 0.35
PGGT1B P53609 1/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
KMT2A Q03164 1/20 0.35
DHODH Q02127 1/20 0.33
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1187716 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL1723760 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL1724050 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL1724226 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL13139046 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL23403885 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL1723665 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL1723691 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL1723689 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA
SCHEMBL29397239 1.00 PTPN1 (0.68) PTPN1PTPN2CDC25BIDO1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344142-B1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS INC (US) 2024-06-26 EP claimed
US-20130053450-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS EDISON PHARMACEUTICALS, INC. (US) 2013-02-28 US claimed
US-20100063161-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS, INC. 2010-03-11 US claimed
EP-2344142-B1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS INC (US) 2024-06-26 EP disclosed
EP-3827815-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC Therapeutics, Inc. (US) 2021-06-02 EP disclosed
US-20210128494-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS BIOELECTRON TECHNOLOGY CORPORATION 2021-05-06 US disclosed
US-10736857-B2 Treatment of pervasive developmental disorders with redox-active therapeutics PTC THERAPEUTICS, INC. (US) 2020-08-11 US disclosed
US-20190083419-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS, INC. 2019-03-21 US disclosed
US-10105325-B2 Treatment of pervasive developmental disorders with redox-active therapeutics BIOELECTRON TECHNOLOGY CORPORATION (US) 2018-10-23 US disclosed
US-20170157065-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS, INC. 2017-06-08 US disclosed
US-9399612-B2 Treatment of pervasive developmental disorders with redox-active therapeutics EDISON PHARMACEUTICALS, INC. (US) 2016-07-26 US disclosed
US-20150239818-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS, INC. 2015-08-27 US disclosed
US-8969420-B2 Treatment of pervasive developmental disorders with redox-active therapeutics EDISON PHARMACEUTICALS, INC. (US) 2015-03-03 US disclosed
US-20140206772-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS, INC. 2014-07-24 US disclosed
US-8653144-B2 Treatment of pervasive developmental disorders with redox-active therapeutics EDISON PHARMACEUTICALS, INC. (US) 2014-02-18 US disclosed
US-20130053450-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS EDISON PHARMACEUTICALS, INC. (US) 2013-02-28 US disclosed
US-8314153-B2 Treatment of pervasive developmental disorders with redox-active therapeutics EDISON PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
US-20100063161-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS PTC THERAPEUTICS, INC. 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170157065-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-10105325-B2 Treatment of pervasive developmental disorders with redox-active therapeutics COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-20140206772-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, DDT, ADH4 PTPN1 2108/4885PTPN2 2060/4885CDC25B 4487/4885
US-20130053450-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-20150239818-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-20100063161-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-10736857-B2 Treatment of pervasive developmental disorders with redox-active therapeutics COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-20190083419-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885
US-20210128494-A1 TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS COMT, ADH4, DDT PTPN1 2118/4885PTPN2 2057/4885CDC25B 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.